Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness Yazdan Yazdanpanah, MD Julian Perelman, PhD Joana Alves Kamal Mansinho, MD Madeline.

Slides:

Advertisements

Similar presentations

Health in Prisons Project Establishing a Monitoring Mechanism on Prison Health Indicators and Health Determinants Working Party on Information on Lifestyle.

Advertisements

Feedback from HIV Europe France: The new recommendation from the French National Authority for Health D Costagliola U943 INSERM and Universite Pierre et.

Institute for Public Health, Medical Decision Making and Health Technology Assessment 1 Results of the PanEuropean Hepatitis C Project 3 rd Paris Hepatitis.

FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.

The projects described were supported by T32 AI007433, R01 AI058736, R01 AI from NIAID, P30 AI from HU CFAR, & NIH Fogarty International Center.

1 Sixty-Four-Slice Computed Tomography of the Coronary Arteries: Cost-Effectiveness Analysis of Patients Presenting to the ED with Low Risk Chest Pain.

The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.

The Clinical and Economic Impact of a Generic First-line Antiretroviral Regimen in the United States Supported by NIAID Rochelle P. Walensky, MD, MPH Paul.

Jason R. Andrews, MD Stephen D. Lawn, MD, DTM&H Corina Rusu, BA, BS Robin Wood, FCP, MMed, DTM&H Farzad Noubary, PhD Melissa A. Bender, MD, MPH Robert.

Expanded HIV Screening in the US: What Will It Cost, and Who Will Pay? A Budget Impact Analysis Erika G. Martin, PhD MPH Rockefeller College of Public.

David Tyas Global HEOR - Lundbeck

Cost-Effectiveness of Cervical Cancer Screening Strategies: Examples from Different World Regions Jane J. Kim, Ph.D. Sue J. Goldie, M.D., M.P.H. Harvard.

European Round Table The Economics of the Widening and Deepening of the EU Tim Josling Stanford Institute for International Studies.

Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.

Sharp L, Tilson L, Whyte S, Ó Céilleachair A

1 Survey Data in ECA : Frequency, Coverage, Consistency and Access By Victor Sulla ECS-PE.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

HIV Screening and Care: Clinical Outcomes, Transmission and Cost A. David Paltiel, PhD Yale University School of Medicine May 9, 2007 National Institute.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

1 Potential Impact and Cost-Effectiveness of the 2009 “Rapid Advice” PMTCT Guidelines — 15 Resource-Limited Countries, 2010 Andrew F. Auld, Omotayo Bolu,

Meredith Carr, JD J. Stan Lehman, MPH David W. Purcell, JD, PhD Division of HIV/AIDS Prevention Centers for Disease Control and Prevention July 25, 2012.

Sexual health in Europe Dr Keith Radcliffe European Regional Director International Union against Sexually Transmitted Infections (IUSTI)

GROWTH DRIVERS AND INVESTMENT OPPORTUNITIES IN EUROPEAN CONSTRUCTION TO 2016 Michael Weingärtler Metal Expert Europe Steel.

NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news EUROCHIP-2 THE ACTION Project & news Public.

© 2005, Johns Hopkins University. All rights reserved. Department of Health, Behavior & Society David Holtgrave, PhD, Professor & Chair.

AIDS IN ASIA – PRIORITIZING AND SUSTAINING THE RESPONSE IN THE ECONOMIC CRISIS Hanoi September 2009 ADB Consultant Ross McLeod.

HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.

Louise Haynes MSW Medical University of South Carolina Lead Investigators: Lisa Metsch PhD Miller School of Medicine, University of Miami Grant Colfax.

Development of Censuses in Europe and Development for EC Statistical Co-operation European Commission (Eurostat) Jurgen Heimann UNFPA/PARIS 21 International.

HTA Regulation and Economic Evaluation in Europe: where are we? Professor Alistair McGuire, LSE, London Istanbul, May 2009.

Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.

The cost-effectiveness of on-site rapid HIV testing in substance abuse treatment: results of the CTN 0032 randomized trial Schackman BR, Metsch LR, Colfax.

Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.

Epidemiologic overview of HIV/AIDS in Ontario and Toronto: 2004 update Robert S. Remis MD, MPH, FRCPC, Maraki Fikre Merid BSc Ontario HIV Epidemiologic.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

How Can Cost Effectiveness Analysis Be Made More Relevant to U.S. Health Care? Paul G. Barnett, PhD February 29, 2012.

USING ECONOMIC EVIDENCE AND STAKEHOLDER'S PARTICIPATION IN DECISION MAKING ON BENEFIT PACKAGE OF UNIVERSAL HEALTH COVERAGE SCHEME IN THAILAND RESULTS:

Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 23: Nov 17, 2008.

Retirement in Europe Annika Sundén Presentation at 16th Annual Meeting of the Retirement Research Consortium “Social Security and the Retirement Income.

International Comparison of Health Care Gene Chang.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

2014 HIV/AIDS Surveillance in the European Union and European Economic Area (EU/EEA) European Centre for Disease Prevention and Control, Stockholm WHO.

The HIV epidemic in Ontario: 2004 update Robert S. Remis, MD, MPH, FRCPC Ontario HIV Epidemiologic Monitoring Unit Department of Public Health Sciences,

Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries Ament A, Baltussen R, Duru G, Rigaud-Bully.

HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Cost-effectiveness of early infant HIV diagnosis and immediate antiretroviral therapy in HIV- infected children

Cancer inequalities in Europe UKACR & NCIN Conference, 17/18 June 2010 Dr. Andrea Micheli Director Descriptive Study and Health Planning Unit Fondazione.

EEA Grants Portugal Mental Health Programme Pedro Mateus National Mental Health Programme.

Semmelweis University Publication Database Semmelweis University Publication Database László Hunyady MD, PhD, DSc Department of Physiology Semmelweis University,

CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.

CT and GC Screening: What about the guys?! Gale R Burstein, MD, MPH, FAAP, FSAHM Erie County Department of Health SUNY at Buffalo School of Medicine Buffalo,

Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.

Cost-effectiveness of initiating and monitoring HAART based on WHO versus US DHHS guidelines in the developing world Peter Mazonson, MD, MBA Arthi Vijayaraghavan,

Table 1. Numbers and rates of TB cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based Source:

European Innovation Scoreboard European Commission Enterprise and Industry DG EPG DGs meeting, May 2008.

Table 1. Number and rate of reported confirmed syphilis cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate,

Table 1. Number and rate of Legionnaires’ disease cases per population by country and year, EU/EEA, 2010–2014 ASR: age-standardised rate, C: case-based.

The clinical impact and cost-effectiveness of incorporating point-of-care (POC) assays into early infant HIV diagnosis (EID) programs at 6 weeks of age.

Presented by: Caitlin Dugdale, MD

HPTN 071 (PopART): Have we reached the targets after two years of the PopART intervention IAS Paris July 2017 Richard Hayes.

Table 1. New HIV diagnoses by country, EU/EEA, 2010–2014

Table 1. Reported confirmed hepatitis A cases: number and rate per population, EU/EEA, 2010–2014 Source: Country reports. Legend: Y = yes, N =

Table 1. Number and rate of reported confirmed syphilis cases per 100 000 population by country and year, EU/EEA, 2010–2014 Country

Selection of cities Anastasios Maroudas Eurogramme

HIV/AIDS Surveillance in Europe 2011

Gonorrhoea cases of gonorrhoea were reported by 27 EU/EEA Member States for The overall notification rate was 18.8 cases per 100 000 population.

The cost-effectiveness of HIV pre-exposure prophylaxis in high-risk men who have sex with men and transgendered women in Brazil Paula M. Luz, Ben Osher,

2006 Rank Adjusted for Purchasing Power

Presentation transcript:

Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness Yazdan Yazdanpanah, MD Julian Perelman, PhD Joana Alves Kamal Mansinho, MD Madeline A. DiLorenzo Ji-Eun Park Elena Losina, PhD Rochelle P. Walensky, MD, MPH Farzad Noubary, PhD Henrique Barros, MD Kenneth A. Freedberg, MD, MSc A. David Paltiel, PhD, MBA

HIV Epidemiological Burden in Portugal % 0.3% 0.2% 0.1% 0% 2009 HIV Prevalence2009 Incidence Per Million Population Luxembourg Italy Ireland Belgium Switzerland Portugal Iceland Spain France Austria UK Netherlands Denmark Sweden Greece Germany Finland Norway

HIV Care in Portugal  The Portuguese National Health Service provides universal coverage for HIV care (including free access to HIV testing and ART) via a national network of public primary care centers and hospitals.  In 2011, the Portuguese Parliament adopted a resolution calling for voluntary, routine population-based HIV testing, counseling and referral (HIV-TCR).  Portugal faces numerous challenges in implementing this resolution.

2010 GDP Challenge: Economic / Fiscal Crisis Source: Eurostat, ACSS <7,600€ 7,600-12,900€ 12,900-20,500€ >20,500€  2010 Portuguese GDP/capita: 16,300€  Mean 2010 EU GDP/capita: 24,000€  2011 GDP growth rate: -1.5%

Regional Disparities 2010 Annual HIV Incidence (%) < > Undiagnosed HIV Prevalence (%) < > 0.20

Objective  To evaluate the clinical impact and cost-effectiveness of routine HIV screening in Portuguese adults (vs. current practice), focusing on the regional heterogeneity in burden of disease.  We examined three different strategies:  One-time screening  Screening every 3 years  Annual screening

 Cost-Effectiveness of Preventing AIDS Complications (CEPAC), a widely published Monte Carlo simulation model of the detection, natural history and treatment of HIV disease.  Assembly of Portuguese national/regional input data on  Epidemiology of HIV infection  HIV clinical care  Economic resource use Methods Overview

VariableValueReference Undiagnosed HIV prevalence 0.16%Portuguese National Institute of Health 2010; Hammers & Philips, HIV Med, 2008 Annual incidence0.02%INSA 2010 Test offer/acceptance rate63.2%Assumption + Jauffret-Roustide, BEH, 2006 Linkage to care rate78.4%Portuguese CAD Report, 2010 Mean CD4 at care initiation 292 cells/μL2010 Survey at 3 Portuguese Hospitals HIV rapid test cost5.40€Ordinance 839-A/2009 Cost of 1 st Line ART (EFV + TDF/FTC) €Portuguese Central Administration of the Health System, 2010 Selected Input Parameters

VariableValueReference Undiagnosed HIV prevalence 0.16%Portuguese National Institute of Health 2010; Hammers & Philips, HIV Med, 2008 Annual incidence0.02%INSA 2010 Test offer/acceptance rate63.2%Assumption + Jauffret-Roustide, BEH, 2006 Linkage to care rate78.4%Portuguese CAD Report, 2010 Mean CD4 at care initiation 292 cells/μL2010 Survey at 3 Portuguese Hospitals HIV rapid test cost5.40€Ordinance 839-A/2009 Cost of 1 st Line ART (EFV + TDF/FTC) €Portuguese Central Administration of the Health System, 2010 Selected Input Parameters

Model Outcomes  Clinical (quality adjusted life years, or QALY)  Economic (per-person lifetime costs, 2010 €)  Incremental Cost-effectiveness (€/QALY)

 World Health Organization Commission on Macroeconomics and Health guidance:  “Cost-effective” if the CE ratio is less than three times the per capita GDP for a given country.  Portuguese GDP per capita is 16,300€, implying a threshold = 48,900 €/QALY.  Portuguese Infarmed “informal threshold” for cost- effectiveness of innovative drugs: ICER < 30,000 €/QALY. Source: Pordata, 2011 Benchmarks for Cost-Effectiveness in Portugal

Testing strategy Quality-adjusted life months HIV-infected 1 Quality-adjusted life months total population 1 Costs (€) 1,2 ICER (€/QALY) 3 Current practice Screen once ,000 Screen every three years ,000 Screen annually ,000 Base Case Results For National Program (Undiagnosed Prevalence = 0.16%, Annual Incidence = 0.02%) 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY. 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY.

Cost-Effectiveness of One-Time HIV Screening in Different Regions 2010 Annual Incidence (%) CE of National One- Time Screening Infarmed Threshold >WHO Threshold WHO CE Threshold > <0.005 CE of Regional One- Time Screening

Cost-Effectiveness of HIV Screening Every Three Years in Different Regions 2010 Annual Incidence (%) CE of National Screening Every 3 Years Infarmed Threshold >WHO Threshold WHO CE Threshold > <0.005 CE of Regional Screening Every Three Years

One-Way Sensitivity Analyses on CE of National, One-Time, Routine Screening HIV test cost (5.4€-42.7€) Mean CD4 at care initiation (255 cells/µL-350 cells/µL) Linkage to care rate (100%-15%) Test acceptance rate (100%-25%) Mean population age (37.6y-42.6y) Infarmed Threshold Base Case WHO Threshold Cost-effectiveness Ratio (€/QALY) First-line ART Costs (512€-732€)

Testing strategy Quality-adjusted life months HIV-infected 1 Quality-adjusted life months total population 1 Costs (€) 1,2 ICER (€/QALY) 3 Current practice , Screen once ,50033,000 Screen every three years ,620dominated* Screen annually ,88048,000 Risk Group Results - MSM (Undiagnosed Prevalence = 3.34%, Annual Incidence = 0.04%) 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY. 4.“dominated”: costs more and confers fewer QALYs than an alternative strategy. 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY. 4.“dominated”: costs more and confers fewer QALYs than an alternative strategy.

Testing strategy Quality-adjusted life months HIV-infected 1 Quality-adjusted life months total population 1 Costs (€) 1,2 ICER (€/QALY) 3 Current practice , Screen once ,21032,000 Screen every three years ,07036,000 Screen annually ,08036,000 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY. 4.“dominated”: costs more and confers fewer QALYs than an alternative strategy. 1.Costs and quality-adjusted life months discounted at 5% per annum. 2.Costs rounded to nearest 10€. 3.ICERs are for the general population and are rounded to nearest 1000€/QALY. 4.“dominated”: costs more and confers fewer QALYs than an alternative strategy. Risk Group Results - IDU (Undiagnosed Prevalence = 6.69%, Annual Incidence = 0.09%)

 A simulation model of HIV screening and disease that combines input data from disparate sources and relies on multiple assumptions.  Impact of expended HIV screening on disease transmission was not considered.  “Cost-effective” ≠ “Affordable”. Budget impact analysis will be a useful next step to understand effects on individual stakeholders. Limitations

Summary and Conclusion  Overall, one-time screening of the national Portuguese population:  is “borderline cost-effective” by informal Portuguese national standards  is cost-effective by WHO standards.  Given the economic crisis as well as the higher disease burden in certain regions, we recommend initiating routine screening in high-prevalence regions first.  More frequent HIV screening may be considered in both high-risk populations (IDUs, MSM) and high-prevalence regions.

Escola Nacional de Saúde Pública – UNL Julian Perelman Joana Alves Céu Mateus João Pereira Instituto de Saúde Pública – U. do Porto Henrique Barros NHS hospitals - Portugal Kamal Mansinho, Ana Cláudia Miranda (CH Lisboa Ocidental) Francisco Antunes, Manuela Doroana (CH Lisboa Norte) Rui Marques (H São João) José Saraiva da Cunha, Joaquim Oliveira (HUC) José Poças (CH Setubal) Eugénio Teófilo (CH Lisboa Central) Acknowledgments Harvard Medical School Kenneth A. Freedberg Elena Losina Rochelle P. Walensky Farzad Noubary Madeline A. DiLorenzo Ji-Eun Park Yale School of Medicine A. David Paltiel Hôpital Bichat – U. Paris Diderot Yazdan Yazdanpanah Funding sources: Coordenação Nacional para a Infecção VIH/SIDA, Agence nationale de recherche sur le SIDA et les hépatites virales, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute on Drug Abuse.